TY - JOUR
T1 - Approaches to preclinical screening of antiangiogenic agents
AU - Kruger, E. A.
AU - Duray, P. H.
AU - Price, D. K.
AU - Pluda, J. M.
AU - Figg, W. D.
N1 - Funding Information:
From the Medicine Branch, the Laboratory of Pathology, and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD. Supported in part by the Office for Research on Health Disparity, National Institutes of Health, the Intramural Program of the National Cancer Institute, and the Angiogenesis Foundation, Inc. Address reprint requests to William D. Figg, PharmD, National Cancer Institute, 10 Center Dr, Sldg JO, Room SA-01, Bethesda, MD 20892. This is a US government work. There are no restrictions on its use. 0093-7754/01/2806-0005$0.00/O doi:10.1053/sonc.2001.28600
PY - 2001
Y1 - 2001
N2 - Angiogenesis, or new blood vessel growth, is essential for the growth, invasion, and metastasis of solid tumors. The inhibition of this process, or antiangiogenesis, is a promising new therapeutic anticancer strategy. Several antiangiogenic compounds are currently in preclinical or clinical development for the treatment of cancer. However, the challenge for the discovery and characterization of antiangiogenic targets remains in developing efficient in vitro or in vivo preclinical angiogenesis screening assays to assess and compare antiangiogenic activity. Several semiquantitative or quantitative angiogenesis assays exist, including in vitro endothelial cell systems and ex vivo or in vivo neovascularization models utilizing mouse, rat, or human tissues. We describe the more common and cost-effective angiogenesis assays currently in use, summarizing their unique advantages and disadvantages. Since angiogenesis inhibition is a novel therapeutic modality towards controlling solid tumors, antiangiogenic drug development underlines the importance in describing, standardizing, and developing quantitative screening assays for the next generation of antiangiogenic agents. This is a US government work. There are no restrictions on its use.
AB - Angiogenesis, or new blood vessel growth, is essential for the growth, invasion, and metastasis of solid tumors. The inhibition of this process, or antiangiogenesis, is a promising new therapeutic anticancer strategy. Several antiangiogenic compounds are currently in preclinical or clinical development for the treatment of cancer. However, the challenge for the discovery and characterization of antiangiogenic targets remains in developing efficient in vitro or in vivo preclinical angiogenesis screening assays to assess and compare antiangiogenic activity. Several semiquantitative or quantitative angiogenesis assays exist, including in vitro endothelial cell systems and ex vivo or in vivo neovascularization models utilizing mouse, rat, or human tissues. We describe the more common and cost-effective angiogenesis assays currently in use, summarizing their unique advantages and disadvantages. Since angiogenesis inhibition is a novel therapeutic modality towards controlling solid tumors, antiangiogenic drug development underlines the importance in describing, standardizing, and developing quantitative screening assays for the next generation of antiangiogenic agents. This is a US government work. There are no restrictions on its use.
UR - http://www.scopus.com/inward/record.url?scp=0035211487&partnerID=8YFLogxK
U2 - 10.1016/S0093-7754(01)90026-0
DO - 10.1016/S0093-7754(01)90026-0
M3 - Article
C2 - 11740811
AN - SCOPUS:0035211487
SN - 0093-7754
VL - 28
SP - 570
EP - 576
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 6
ER -